公开(公告)号：US20190263919A1

公开(公告)日：2019-08-29

申请号：US16310725

申请日：2017-06-30

Applicant: Five Prime Therapeutics, Inc.

Inventor： Susan Foy ,  Thomas Brennan ,  Danielle Kellar

IPC: C07K16/28 ,  A61K35/17 ,  A61P35/00 ,  A61K31/7125 ,  A61K9/00 ,  A61K38/17

Abstract: The present disclosure relates to methods of using glucocorticoid-induced TNFR-related protein (GITR) agonists as anti-tumor agents, for example in combination with CpG oligodeoxynucleotides. A specific antibody, characterized by its CDRs is described as agonist.

公开(公告)号：US20190248908A1

公开(公告)日：2019-08-15

申请号：US16256311

申请日：2019-01-24

Applicant: Five Prime Therapeutics, Inc.

Inventor： Brian Wong ,  Emma Masteller ,  Kris Reedquist

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.

公开(公告)号：US20190175730A1

公开(公告)日：2019-06-13

申请号：US16181784

申请日：2018-11-06

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas Harding ,  Kristen Pierce ,  Namrata Patil ,  Thomas Brennan ,  Julie Hambleton

IPC: A61K39/395 ,  A61K31/513 ,  A61K31/337 ,  A61K33/24 ,  A61K45/06 ,  C07K16/28

Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.

公开(公告)号：US20190135911A1

公开(公告)日：2019-05-09

申请号：US16096699

申请日：2017-04-21

Applicant: Five Prime Therapeutics, Inc. ,  GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

Inventor： Kathleen M. SULLIVAN ,  Katherine Kurylo ,  Paul Redford ,  Soren Beinke ,  David Michalovich ,  Karen Simpson ,  Edith Hessel

IPC: C07K16/24 ,  A61P11/00 ,  A61P31/22 ,  A61P31/06

Abstract: Provided herein are methods for treating or preventing a respiratory disease, such as chronic obstructive pulmonary disease (COPD), by reducing or inhibiting interleukin 4 inducible 1 (IL4I1) activity.

公开(公告)号：US20190119390A1

公开(公告)日：2019-04-25

申请号：US16015371

申请日：2018-06-22

Applicant: Five Prime Therapeutics, Inc.

Inventor： Robert Sikorski ,  Julie Hambleton ,  Nilacantan Sankar

IPC: C07K16/28

Abstract: Methods of treating pigmented villonodular synovitis (PVNS) with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.

公开(公告)号：US10221244B2

公开(公告)日：2019-03-05

申请号：US15680664

申请日：2017-08-18

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Brian Wong ,  Julie Hambleton ,  Robert Sikorski ,  Emma Masteller ,  Kevin Hestir ,  David Bellovin ,  Katherine E. Lewis

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  A61K39/00

Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.

公开(公告)号：US10221243B2

公开(公告)日：2019-03-05

申请号：US15154822

申请日：2016-05-13

Applicant: Five Prime Therapeutics, Inc.

Inventor： Brian Wong ,  Emma Masteller ,  Kris Reedquist

IPC: A61K39/395 ,  C07K16/28 ,  A61K45/06 ,  A61K39/00

Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.

公开(公告)号：US20180280470A1

公开(公告)日：2018-10-04

申请号：US15861047

申请日：2018-01-03

Applicant: Five Prime Therapeutics, Inc. ,  GlaxoSmithKline Intellectual Property (No. 2) Limited

Inventor： Julie Hambleton ,  Maureen Bleam ,  Maurice P. DeYoung ,  Geraldine Ferron-Brady ,  Rakesh Kumar ,  Lone Ottesen

IPC: A61K38/17

Abstract: Methods of treating cancers comprising FGFR1 gene amplification, FGFR1 overexpression, FGFR3 overexpression, FGFR3 amplification, FGF2 overexpression, and/or FGF2 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent. In some embodiments, methods of treating cancers comprising administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one chemotherapeutic agent are provided.

公开(公告)号：US10040858B2

公开(公告)日：2018-08-07

申请号：US14976346

申请日：2015-12-21

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Robert Sikorski ,  Julie Hambleton ,  Nilacantan Sankar

IPC: C07K16/28 ,  A61K39/395 ,  A61K39/00

Abstract: Methods of treating pigmented villonodular synovitis (PVNS) with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.

公开(公告)号：US20180147271A1

公开(公告)日：2018-05-31

申请号：US15575220

申请日：2016-05-17

Applicant: bluebird bio, Inc. ,  Five Prime Therapeutics, Inc. ,  Eureka Therapeutics, Inc.

Inventor： Richard MORGAN ,  Robert SIKORSKI ,  Brian WONG ,  Emma MASTELLER ,  Luis BORGES ,  Cheng LIU ,  Yiyang XU

IPC: A61K39/00 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  A61P35/02

CPC classification number: A61K39/0011 ,  A61K2039/505 ,  A61P35/02 ,  C07K14/7051 ,  C07K16/2803 ,  C07K16/30 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/03 ,  C07K2319/74

Abstract: The invention provides improved compositions for adoptive cell therapies for cancers that express ROR1.